Study: Many approved cancer drugs lack proof of added benefit

Many cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved through expedited (“fast track”) pathways, finds a study published by The BMJ today.

First-of-its-kind study reveals a new culprit in the formation of brain hemorrhages

A first-of-its-kind study led by the University of California, Irvine has revealed a new culprit in the formation of brain hemorrhages that does not involve

November 20, 2023

Study reveals how NPAS4 regulates drug-context associations and impacts relapse

Most people wouldn’t think twice after seeing sugar spilled on a counter. But for someone with a history of cocaine use, this visual cue could

August 10, 2024

FDA approves Takeda’s colorectal cancer drug Fruzaqla – Pharmaceutical Technology

The drug is already approved in China and is also currently under review for marketing authorisation by the European Medicines Agency (EMA). Image credit: Shutterstock/Tada

November 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.